Patents by Inventor Barry Peter Clark

Barry Peter Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8575214
    Abstract: The present invention provides novel mGlu2/3 agonists of the formula wherein R1, R2, and R3 are as defined herein, for use in the treatment of neurological or psychiatric disorders.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 5, 2013
    Assignee: Eli Lilly and Company
    Inventors: Stephen Richard Baker, Christopher David Beadle, Barry Peter Clark, James Allen Monn, Lourdes Prieto
  • Patent number: 8202873
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently —C(H)? or —N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R1-4 are as defined herein.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: June 19, 2012
    Assignee: Eli Lilly and Company
    Inventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
  • Publication number: 20100120785
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)? or N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R14 are as defined herein.
    Type: Application
    Filed: May 7, 2008
    Publication date: May 13, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
  • Patent number: 7619096
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).
    Type: Grant
    Filed: May 11, 2004
    Date of Patent: November 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, Manuel Javier Cases-Thomas, Barry Peter Clark, Peter Thaddeus Gallagher, John Joseph Masters, Graham Henry Timms, Magnus Wilhelm Walter, Maria Ann Whatton, Virginia Ann Wood, Jeremy Gilmore
  • Patent number: 7615648
    Abstract: The present invention provides compounds of formula (I) wherein A is (1), (2), (3), (4), (5), (6) or (7) and wherein R1, R7, y and Ar1 are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such, may be useful in the treatment of disorders of the central and/or peripheral nervous system.
    Type: Grant
    Filed: May 19, 2005
    Date of Patent: November 10, 2009
    Assignee: Eli Lilly and Company
    Inventors: John Richard Harris, Barry Peter Clark, Peter Thaddeus Gallagher, Maria Ann Whatton
  • Patent number: 7521462
    Abstract: The present invention provides compounds of formula (I) where n, R1, R2, R3, R4, R5 and Heteroaryl are defined herein. The compounds are inhibitors of the uptake of one or more monoamines selected from serotonin, norepinephrine and dopamine and, as such, may be useful in the treatment of disorders of the central and/or peripheral nervous system.
    Type: Grant
    Filed: February 11, 2005
    Date of Patent: April 21, 2009
    Assignee: Eli Lilly and Company
    Inventors: Serge Louis Boulet, Barry Peter Clark, John Fairhurst, Peter Thaddeus Gallagher, Anette Margareta Johansson, Maria Ann Whatton, Virginia Ann Wood
  • Patent number: 7488728
    Abstract: The invention relates to compounds of formula (I): wherein R, R1, R2 and X are defined herein, their preparation, and their use as pharmaceuticals.
    Type: Grant
    Filed: August 9, 2004
    Date of Patent: February 10, 2009
    Assignee: Eli Lilly and Company
    Inventors: Barry Peter Clark, Peter Thaddeus Gallagher
  • Patent number: 7432280
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: October 7, 2008
    Assignee: Eli Lilly and Company
    Inventors: Christopher David Beadle, Manuel Javier Cases-Thomas, Barry Peter Clark, Peter Thaddeus Gallagher, John Joseph Masters, Graham Henry Timms, Magnus Wilhelm Walter, Maria Ann Whatton, Virginia Ann Wood, Jeremy Gilmore
  • Patent number: 7384941
    Abstract: Compounds of formula (I): wherein A is S or O; R is H; Ar is an optionally substituted phenyl group; X is an optionally substituted phenyl group, a C1-C4 alkyl, a C3-C6 cycloalkyl group or a CH2(C3-C6 cycloalkyl) group; R? is H or C1-C4 alkyl; and each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof are selective inhibitors of norepinephrine reuptake.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: June 10, 2008
    Assignee: Eli Lilly and Company
    Inventors: Magnus Wilhelm Walter, Barry Peter Clark, Peter Thaddeus Gallagher, Helen Louise Haughton, Hélène Catherine Eugénie Rudyk
  • Patent number: 7294623
    Abstract: A compound of formula (I) (I) wherein R is H; Ar is an aromatic group selected from phenyl; X is a phenyl group; R? is H or C1-C4 alkyl; each R1 is independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereof
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: November 13, 2007
    Assignee: Eli Lilly and Company
    Inventors: Barry Peter Clark, Peter Thaddeus Gallagher, Helen Louise Haughton
  • Patent number: 6482824
    Abstract: Use of a compound of formula (I) in which, R1, R2 and R3 are independently hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, C3-C10)cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted aryl(C1-C6)alkyl, unsubstituted or substituted aryl(C2-C6)alkenyl, halo, carboxy, (C1-C6)alkoxycarbonyl or —(CH2)m—OH wherein m is 1, 2 or 3; - - - indicates a single or a double bond; X and each independently hydrogen, or X and Y together represent a bridge of the formula —CH2)m—, where n is 1 or 2; A1 and A2 are each independently an unsubstituted or substituted aryl; Z is —CO—, —SO2— or —CH2; provided that, when Z is —CO—, A1 is not 3,4,5-trimethoxyphenyl; or a pharmaceutically-acceptable salt or ester thereof, for the manufacture of a medicament for the treatment of a condition indicating the administration of a selective mGluR1 antagonist.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: November 19, 2002
    Assignee: Eli Lilly and Company
    Inventors: Barry Peter Clark, John Richard Harris, Ann Elizabeth Kingston
  • Patent number: 6054448
    Abstract: Compounds of the formula ##STR1## in which R.sup.1 is Y or Y--C.sub.1-6 alkyl, where Y is carboxy, tetrazolyl, --SO.sub.2 H, --SO.sub.3 H, --OSO.sub.3 H, --CONHOH, or --P(OH)OR', --PO(OH)OR', --OP(OH)OR' or --OPO(OH)OR' where R' is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or optionally substituted phenyl-C.sub.1-6 alkyl,and R.sup.2, R.sup.3, R.sup.4, X and Z are as defined in the specification, possess affinity for metabotropic glutamate receptors and are useful in the treatment of disorders of the central nervous system.
    Type: Grant
    Filed: October 17, 1997
    Date of Patent: April 25, 2000
    Assignee: Eli Lilly and Company Limited
    Inventors: Barry Peter Clark, John Richard Harris
  • Patent number: 5891899
    Abstract: A pharmaceutical compound of the formula: ##STR1## in which A is carboxy, tetrazolyl, --SO.sub.2 H, --SO.sub.3 H, --OSO.sub.3 H, --CONHOH, or --P(OH)OR', --PO(OH)OR', --OPO(OH)OR'B is a bond, C.sub.1-6 alkylene or C.sub.2-6 alkenylene,R.sup.1 is hydrogen, hydroxyl, halo or group of the formula A--B--,X is C.sub.1-6 alkylene, C.sub.2-6 alkenylene, C.sub.2-6 alkynylene or C.sub.1-6 alkylene linked through --O--, --S-- or --NR"-- to Y, where R" is hydrogen or C.sub.1-6 alkyl,andY is (1) ##STR2## where p is and Z is ##STR3## or (2) ##STR4## and salts and esters thereof.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: April 6, 1999
    Assignee: Eli Lilly and Company Limited
    Inventors: Barry Peter Clark, John Richard Harris
  • Patent number: 5863947
    Abstract: A pharmaceutical compound of the formula: ##STR1## in which R.sup.1 is hydrogen, hydroxy or C.sub.1-6 alkoxy, R.sup.2 is hydrogen, carboxy, tetrazolyl, --SO.sub.2 H, --SO.sub.3 H, --OSO.sub.3 H, --CONHOH, or --P(OH)OR', --PO(OH)OR', --OP(OH)OR' or --OPO(OH)OR' where R' is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or aryl C.sub.1-6 alkyl,R.sup.3 is hydrogen, hydroxy or C.sub.1-4 alkoxy, andR.sup.4 is fluoro, trifluoromethyl, nitro, C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkylthio, heteroaryl, optionally substituted aryl, optionally substituted aryl C.sub.1-6 alkyl, optionally substituted aryl C.sub.2-6 alkenyl, optionally substituted aryl C.sub.2-6 alkynyl, optionally substituted aryloxy, optionally substituted aryl C.sub.1-6 alkoxy, optionally substituted arylthio, optionally substituted aryl C.sub.1-6 alkylthio or --CONR"R'", --SO.sub.2 NR"R"", --NR"R'", --OCONR"R"' or --SONR"R'" where R" and R'" are each hydrogen, C.sub.1-6 alkyl or aryl C.sub.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: January 26, 1999
    Assignee: Eli Lilly and Company Limited
    Inventors: Stephen Richard Baker, Barry Peter Clark, John Goldsworthy, John Richard Harris